Floatz logo

Personalized Neoantigen Mrna Tumor Vaccine

Posto Perative Hepatocellular Carcinoma

Shanghai Zhongshan HospitalvaccineN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

520 Active assets in the Posto Perative Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Personalized Neoantigen Mrna Tumor Vaccine is also rated in:

Solid Tumor MalignanciesDormant
C
Indicative ·
36 / 100
View asset →
esophageal squamous cell carcinomaDormant
D
Indicative ·
30 / 100
View asset →
gastric adenocarcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →